Correction to: Efficacy and Safety of Switching to Ixekizumab in Etanercept Non-Responders: A Subanalysis from Two Phase III Randomized Clinical Trials in Moderate-to-Severe Plaque Psoriasis (UNCOVER-2 and -3)
Crossref DOI link: https://doi.org/10.1007/s40257-018-0353-x
Published Online: 2018-03-29
Published Print: 2018-06
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Blauvelt, Andrew
Papp, Kim A.
Griffiths, Christopher E. M.
Puig, Luis
Weisman, Jamie
Dutronc, Yves
Kerr, Lisa Farmer
Ilo, Dapo
Mallbris, Lotus
Augustin, Matthias
Text and Data Mining valid from 2018-03-29
Article History
First Online: 29 March 2018